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Abstract
Background Surgery for gliomas is often confounded by difficulties in distinguishing tumor from surrounding normal brain. For
better discrimination, intraoperative optical imaging methods using fluorescent dyes are currently being explored.
Understandably, such methods require the demonstration of a high degree of diagnostic accuracy and clinical benefit.
Currently, clinical utility is determined by tissue biopsies which are correlated to optical signals, and quantified using measures
such as sensitivity, specificity, positive predictive values, and negative predictive values. In addition, surgical outcomes, such as
extent of resection rates and/or survival (progression-free survival (PFS) and overall survival (OS)) have been measured. These
assessments, however, potentially involve multiple biases and confounders, which have to be minimized to ensure reproducibil-
ity, generalizability and comparability of test results. Test should aim at having a high internal and external validity. The objective
of this article is to analyze how diagnostic accuracy and outcomes are utilized in available studies describing intraoperative
imaging and furthermore, to derive recommendations for reliable and reproducible evaluations.
Methods A review of the literature was performed for assessing the use of measures of diagnostic accuracy and outcomes of
intraoperative optical imaging methods. From these data, we derive recommendations for designing and reporting future studies.
Results Available literature indicates that potential confounders and biases for reporting the diagnostic accuracy and usefulness of
intraoperative optical imaging methods are seldom accounted for. Furthermore, methods for bias reduction are rarely used nor
reported.
Conclusions Detailed, transparent, and uniform reporting on diagnostic accuracy of intraoperative imaging methods is necessary.
In the absence of such reporting, studies will not be comparable or reproducible. Future studies should consider some of the
recommendations given here.
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Introduction
During high-grade glioma (HGG) surgery, the infiltrative tu-
mor margin is difficult to visualize during surgery. Inadvertent
residual enhancing tumor is left behind when the surgeon
relies only on differences in tissue color or texture for identi-
fying tumor [5, 85]. For this reason, a number of surgical
adjuncts or imaging technologies have been introduced during
the last three decades which help the surgeon identify tumor
tissue intraoperatively, such as neuronavigation, intraopera-
tive MRI (iMRI) [9], ultrasound [37], and fluorescence
guidance.
5-Aminolevulinic acid (5-ALA) has been the most widely
studied agents used in fluorescence-guided surgery (FGS) of
HGGs and is approved in different countries around the globe
[6, 31, 61, 79, 84, 85, 100]. Off-label use of fluorescein sodi-
um for FGS has been investigated in patient cohorts [2, 3, 18,
25, 50, 62, 64, 78], in addition to indocyanine green (ICG)
[105]. Targeted fluorescence markers are under preclinical
development and are slowly translating into the human setting
[29, 51, 91].
Effective intraoperative fluorescence imaging relies on the
assumptions that highlighted tissues truly represent tumor, that
non-highlighted tissue presents normal brain, and that the
targeted tissue corresponds to the pathology as delineated by
preoperative imaging, e.g., MRI contrast enhancement in
HGGs.
Therefore, diagnostic methods or tests proposed for prov-
ing intraoperative clinical reliability require precise evalua-
tions to ensure they truly predict the presence or absence of
tumor tissue in the brain, and provide the surgeon the infor-
mation to decide (in conjunction with concerns for safety),
whether further tumor resection should be performed. In ad-
dition to demonstrating a correlation between the signal of the
intraoperative method and histology, the FDA requires a proof
of clinical benefit for approval which does not necessarily
include proof of improved survival [94]. For this purpose,
detailed studies are necessary prior to regulatory approval
and marketing of such methods.
At present, no detailed, consented criteria for testing the
diagnostic accuracy or clinical benefit of intraoperative fluo-
rescence imaging are available. Such criteria would allow
comparability and reproducibility of methods. The compara-
tive performance of such methods would ultimately be of
interest for their future development and application.
Available guidelines on diagnostic accuracy, e.g., STARD
(Standards for Reporting of Diagnostic Accuracy) [11, 71], do
not address the particular requirements for intraoperative test-
ing with its many confounders and inherent clustering of data.
Although the basic principles for reporting on the accuracy of
diagnostic tests are reflected herein, they have been construct-
ed for diagnostic tests, which give one value per patient.
Both the Federal Drug Administration (FDA) and the
European Medicines Evaluation Agency (EMA) provide
guidance on the evaluation of diagnostic tests. The FDA’s
“Statistical Guidance on Reporting Results from Studies
Evaluating Diagnostic Tests” explicitly does not pertain to
testing multiple samples from single patients, which would
typically be the case for intraoperative tissue assessments.1
EMA’s “Guideline on Clinical Evaluation of Diagnostic
Agents”2 includes recommendations for testing various
stains/markers, e.g., stains used intraoperatively in detection
of malignant mucosal lesions, recommending test perfor-
mance to be expressed both in relation to an overall individual
(per patient basis) and to lesions detected and/or organs or
sites involved (per lesion or per site basis). However, EMA
also does not address the numerous confounders and biases
that might be encountered during testing for intraoperative
fluorescence in the brain (as reviewed in the following), or
other organs.
This review will discuss possible pitfalls and biases in-
volved in testing intraoperative fluorescence, will analyze
the available literature on how such biases have been handled,
and make suggestions on possible guidelines for intraopera-
tive diagnostic testing.
While this review focusses on widefield fluorescence im-
aging, which is in broad clinical use, it explicitly pertains to
other methods of intraoperative tissue diagnosis as well, e.g.,
RAMAN spectroscopy, for which ample literature is available
[13, 14, 24, 45, 47, 48].
Classical evaluation of diagnostic tests
Diagnostic testing for correctly identifying disease or health
prior to treatment decisions is a universal necessity in medi-
cine. The expression “test” signifies any technique for deter-
mining whether subjects present a certain physical status or
condition, e.g., if he is afflicted with a certain disease. For
evaluating the accuracy of a diagnostic test, studies are used
in which test results are compared to a reference or gold stan-
dard [11]. Reference standards may be laboratory examina-
tions, imaging, pathological data, or clinical outcomes.
Resulting test values may be binary or dichotomous (with
two qualities, e.g., disease or no disease), quantitative (or con-
tinuous, e.g., PSA for detecting prostate cancer, or other lab-
oratory values), or semi-quantitative (on an ordinal scale, e.g.,
test strips for detecting sugar in urine [81]).
Many diagnostic tests are based on laboratory values,
which ideally, if present or exceeding a certain level, will
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unambiguously indicate that a patient has a disease, whereas
all other patients are disease-free. Due to the inevitable vari-
ability inherent to biological systems, however, such unam-
biguous tests are rare. Rather, there is usually some degree of
overlap between test values in diseased and non-diseased pa-
tients based on the distribution of test values in either
population.
Thus, with the same value of the diagnostic test, one patient
may be afflicted with a condition whereas the other is healthy.
Tests are therefore assessed for their diagnostic accuracy, i.e.,
the amount of agreement between the test, which is being
assessed, and the reference standard which unequivocally de-
notes disease [11, 35].
To characterize diagnostic accuracy different measures or
terms have been introduced which give information on the
performance of tests, derived from the frequency with which
a laboratory test or test value truly or falsely indicates disease,
or misses the presence of disease, as summarized in Table 1.
Using common measures of diagnostic accuracy
for intraoperative tissue diagnosis in the brain
How can traditional methods of diagnostic testing be used for
testing the accuracy of intraoperative optical tissue diagnosis
in brain tumor surgery?
The most important difference between studies on diagnos-
tic tests that test for the presence of disease in the conventional
sense, and intraoperative tissue diagnosis is that traditional
measures were developed with every patient generating a sin-
gle measurement. Hence, individual measurements, being
from individual patients, are independent. On the other hand,
studies evaluating the accuracy of intraoperative tumor diag-
nostics will typically be based on histology, and it will not
suffice to take only one tissue sample per patient. Rather,
multiple samples (clusters) will be collected per patient relat-
ing the signal of the detection method and the reference stan-
dard, histology. Multiple samples from single patients will
render these clustered samples interdependent, an aspect
which requires special consideration when assessing the accu-
racy of such tests.
The argument that intraoperative optical tissue diagnosis
can be assessed in as simple a fashion as a laboratory test for
the presence of disease therefore requires careful scrutiny.
Simply adapting traditional diagnostic accuracy measure-
ments to biopsies during brain tumor surgery is per se flawed,
since samples are all collected in the diseased subject or organ
but not from healthy subjects. In addition, biopsies in the brain
will never be random, especially if the brain looks normal.
Hypothetically, the entire brain should be sampled with an
infinite number of samples and analyzed to determine whether
the volume of tissue detected by the optical method coincides
with the volume of the tumor, i.e., to determine whether the
test detects the entire tumor and the result of the test is truly
dichotomous (all tumor detected or not). Needless to say, this
is not an option. In practice, the sample volume is restricted by
craniotomy and corticotomy to the area of the gross tumor and
its immediate surroundings.
In addition, investigators are strongly limited by the num-
ber of samples they can collect, especially in normal
appearing brain. They will have to rely on a finite number
of intraoperative biopsies for histological comparisons. To do
so, investigators will take samples from non-highlighted and
from tissues highlighted by their diagnostic method and then
examine samples histologically. Most biopsies will not be tak-
en from normally appearing brain but rather from irregular
brain tissue for obvious ethical reasons.
Thus, in contrast to the single laboratory value for a single
patient (e.g., PSA for prostate cancer), trying to establish di-
agnostic accuracy in the brain from intraoperative tissue sam-
ples is compromised by numerous confounders and potential
biases (with “bias” being defined as the result of systematic
flaws or limitations in the design or conduct of a study, which
distort the results [99]).
Another aspect which requires attention in the brain is the
fact that gliomas are diffusely infiltrating tumors with cell
densities tapering into surrounding brain. Tissue biopsies will
Table 1 Diagnostic decision matrix for diagnostic accuracy
True disease state
Present Absent
Test result Positive True positive (TP)
The test is positive and the subject suffers the disease
False positive (FP)
The test is positive whereas the subject is healthy
Negative False negative (FN)
The test is negative, yet the patient suffers the disease
True negative (TN)
The test is negative and the subject is healthy
Measure Definition Calculation
Sensitivity probability of a positive test result when a subject has the disease TP/(TP + FN)
Specificity Probability of a test being negative if a patient does not have the disease TN/(TN + FP)
Positive predictive value Probability that the patient has the disease if the test is positive TP/(TP + FP)
Negative predictive
value
Probability that the patient is disease free if the test is negative TN/(TN + FN)
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not only give dichotomous results (tumor or not tumor).
Rather, biopsies will reveal a variable degree of infiltration.
The likelihood of finding tumor cells in biopsies, i.e., the
prevalence of tumor cells, will depend on the distance of the
biopsy from the main tumor mass. Traditional values for di-
agnostic accuracy will depend on where the biopsies are being
taken, resulting in possible biases (Fig. 1a and b). Other biases
allude to the way individual tissue samples are dissected for
analysis (Fig. 2), the timing of surgery after application of the
fluorochrome (Fig. 3), the type of staining used for identifying
single tumor cells, or the number of samples taken in a certain
tissue region.
An example of how biopsy numbers directly affect results
of diagnostic testing is given in Table 2. Furthermore,
intermixing biopsies from different patients if the numbers
per patient vary, will lead to differing results depending on
Fig. 1 a Influence of tissue
allocation bias type 1 on the NPV
and specificity. Since gliomas are
infiltrating tumors and the density
of infiltrating cells will decrease
rapidly with distance from the
tumor bulk, the calculated NPV
and specificity will be higher the
further away from the tumor
samples are collected because of
the lower likelihood for falsely
negative samples. b Influence of
tissue allocation bias type 1 on
PPVand sensitivity. The
likelihood for finding falsely
positive biopsies will depend on
the location of biopsies. If
samples are collected
predominantly in the main tumor
mass, the calculated PPVand
sensitivity will be high. If samples
are collected at the margins and
the diagnostic method unreliably
detects tumor, the PPV will be
lower
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how these are handled (Table 3). In methods with a relevant
signal-to-noise ratio that requires the creation of a threshold
because of background signal, this threshold will determine
the results of the test.
Table 4 summarizes possible biases involved in assessing
the accuracy and efficacy of intraoperative diagnostic
methods.
Test result reproducibility
Multiple technical and human factors will influence the repro-
ducibility of an intraoperative imaging test.
Technical equipment may be sensitive or insensitive in
generating, detecting, and conveying the optical signal to the
surgeon, and signals may vary over time due to influence by
multiple factors. For example, the distance of the microscope
from the illuminated cavity will determine the intensity of
light reaching the cavity, which in turn will be linearly related
to fluorescence intensity and may influence detection sensitiv-
ity. Typically, xenon light sources will have fluctuations and
light intensity can deteriorate over time, thereby also influenc-
ing the strength of the signal. Lasers will fluctuate and will
require calibration. In fluorescence, detection filters are some-
times configured to allow background light to pass.
Depending on the intensity of the background signal, the test
signal might be less easily detected due to background trans-
mission of excitation light. Such effects will reduce contrast.
An example for this is the Yellow 560 Zeiss, which allows a
strong background signal to pass, thereby reducing the sensi-
tivity for signal visualization. Indocyanine green (ICG) as a
near-infrared (NIR) fluorochrome is invisible to the human
eye and requires image processing to account for pulsation
artifacts or large fluctuations in signal intensity after adminis-
tration. Ambient light will interfere with tissue fluorescence in
5-ALA- induced f luorescence -gu ided resec t ion .
Photobleaching might play a role with all fluorochromes [86].
Fig. 3 Timing and threshold bias pertinent for fluorochromes that are
applied i.v. that do not have any specific tumor affinity (e.g., fluorescein
sodium, Diaz et al. 2015), or expected to have selective affinity (targeted
fluorochromes, e.g., APC-analoga, Swanson et al. 2015). This graph
illustrates the course of fluorescence in different tissue compartments.
(A) After i.v. injection, concentrations will be high in blood vessels, all
perfused tissues, and will slowly abate. (B) Due to extravasation through
BBB disruption within malignant tumor, pseudo-selectivity will ensue;
this effect will also pertain to any areas of surgically induced BBB dam-
age, e.g., the resection margin. (C) Meanwhile, extravasated fluorophore
propagates with edema into peritumoral tissue in an unspecific manner.
The apparent diagnostic accuracy will strongly depend on the definition
of thresholds and on time after injection. (D) For targeted fluorochromes,
selective retention can be expected after clearance from edema and plas-
ma. These curves directly the signal-to-noise ratio, which changes over
time
Fig. 2 Tissue allocation bias type 3. Intraoperative optical diagnostic
information is usually two-dimensional, i.e., only giving superficial
information from the exposed tissue. The biopsy, on the other hand, is
three-dimensional and assessment of only a part of the biopsy might miss
the pathology
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Also, interobserver variation will have an impact on the
reproducibility when assessments are qualitative and depen-
dent on personal judgment. An extreme example for this
would be the difficulty of colorblind surgeons in differentiat-
ing red porphyrin fluorescence [67].
Some studies use technical methods for detecting specific
signals from tumors, such as multiple channel spectroscopical
fluorescence and/or reflectance, and generate algorithms to
identify tumors based on these multiple tissue characteristics.
For such methodologies, derived from training sets, with pro-
cessing of multiple characteristics to give a final algorithm for
tissue identification, a validation is required, e.g., cross-vali-
dation or independent test cohort. The validation is crucial to
guarantee the applicability of the algorithms to data sets that
differ from the particular data set used to generate the algo-
rithm [15, 23].
Alternate reference standards
It is evident that histology is an important reference standard,
or standard of truth. On the other hand, histology, even when a
number of biopsies are obtained, will not give information
about the entire tumor or the entire brain. Thus, an alternate
outcome might be the completeness of tumor resection based
on the intraoperative optical imaging method, as assessed by
postoperative imaging, e.g., in how many cases was “com-
plete” resection of the contrast-enhancing portion of tumor
possible? In infiltrating lesions such as gliomas, it is necessary
to define what should be considered as resection target on
MRI. Traditionally, resection of enhancing tumor is consid-
ered as the target in high-grade glioma surgery [75, 86],
whereas in low-grade gliomas, it is currently the FLAIR-
weighted abnormality [57, 82]. However, tumor resection
rates do not only depend on intraoperative optical methods
for identifying residual tumors. The extent of resection will
also be strongly influenced by patient selection (small, non-
eloquent tumors vs. larger, eloquent tumors), the availability
of intraoperative mapping/monitoring for safely performing
maximal tumor resections, or the experience of the surgeon.
Since these factors will differ from center to center and from
surgeon to surgeon, single arm, monocentric studies will be
confounded due to bias in patient selection, available resection
technologies, and the surgeon. Thus, using the completeness
of resection as an endpoint for evaluating intraoperative diag-
nostic methods will require randomized trials or prospective
cohort studies, where propensity score matching or multivar-
iable statistical methods should be applied in the analysis.
A similar argumentation pertains to outcome, i.e., survival,
progression-free survival, and neurological safety. Survival
has been used outside of randomized studies to indicate the
benefit of a method [2].
Survival as outcome will not be directly related to the di-
agnostic method but rather to extent of tumor resection.
Completeness of tumor resection will be under some influence
of useful intraoperative optical methods, but not exclusively
so, since the surgeon, who is aware of brain contrasted by a
particular method may not resect tumor due to safety con-
cerns. In the 5-ALA randomized, controlled trial in both study
arms surgeons decided not to take residual visible tumor in
30% of cases due to concerns for neurological function [86].
The same limitations apply as stated for postoperative imag-
ing. Outcomes could only be interpreted confidently when
studied in prognostically balanced cohorts, which can only
be achieved by randomization. However, the effects of the
diagnostic method on outcome will be small since many other
factors influence survival and resection rates. The outcome
advantage would not be conferred by the use of the diagnostic
method but “merely” by increasing the rates of more “com-
plete” resections. Complete resections would also be observed
in the control arm, and not all patients in the arm with the new
diagnostic method would have complete resections for func-
tional reasons. Thus, any effects of the intraoperative diagnos-
tic method on outcome, for example time to progression or
Table 2 How with a given diagnostic method, differences in the number of biopsies obtained from certain regions, based on the sampling algorithm
chosen by investigator A compared to investigator B, will strongly influence the results for the measures of diagnostic accuracy
Tumor center Tumor margin Normal tissue Sens Spec NPV PPV




0.78 0.75 0.6 0.78




0.67 0.66 0.66 0.6
In this hypothetical example, only the number of truly positive samples from the tumor center was varied, causing a relevant difference in sensitivity and
positivity (italic entries).
Table 3 How pooling samples from different patients influences results
TP FP TN FN Sensitivity Specificity
Patient A 10 1 5 1 0.91 0.83
Patient B 1 1 1 1 0.50 0.50
Average measures 0.71 0.67
Pooled biopsies 11 2 6 2 0.78 0.75
The two hypothetical assessments differ only in the number of samples
taken by investigators per site with a particular method
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Table 4 Potential biases and confounders in establishing diagnostic accuracy of intraoperative optical diagnostics
Bias type Explanation
Tissue allocation bias type A The location from where samples are collected relative to the signal margin will directly influence the
apparent accuracy of the diagnostic test that is being evaluated, i.e., the calculations of specificity and
sensitivity, the negative predictive value (NPV) and the positive predictive value PPV (Fig. 1a and b).
This is due to the fact that during intraoperative diagnostic testing in a typical, infiltrating brain tumor the
prevalence of tumor cells is high in its center, whereas at the infiltratingmargin the prevalence of tumor
cells is lower and decreases with distance away from the tumor bulk. If samples are taken immediately
beyond the margins of the highlighted tumors, the likelihood of finding unmarked, falsely negative
tumor cells (FN) will be higher than if the samples are taken at a distance using the same method. This
will directly affect NPVand specificity. Conversely, if marked tissue samples are taken only at the
center of the tumor, the prevalence of tumor cells will be high and the rate of false positive samples low,
and the calculation of PPVor sensitivity will give high values. When samples are taken at the more
critical margin using the same method, it is to be expected that the rate false positive samples will be
higher and the values for sensitivity and PPV lower.
However, in practice PPVand sensitivity will not be as susceptible to such strong effects as the NPVand
specificity, since invariably the surgeon will primarily target gross tumor, as defined by
neuronavigation, ultrasound, or the optical impression under conventional illumination, and
(understandably) not adjacent inconspicuous brain.
This bias can be made transparent by describing exactly the position of the biopsy relative to the signal
margin.
Tissue allocation bias type B With methods that provide ambiguous signals, investigators are more likely to sample areas of the tumor
that are judged to be abnormal with conventional illumination, e.g., by texture or color, than the
inconspicuous margins, which might look like normal brain. Thus, the likelihood for true positive
samples may be highwith such methods despite the limitations of the method for detecting tumor at the
margins. In other words, the distribution of the optical signal or tissue characteristics with conventional
illumination will influence the surgeon not to adhere to a truly random biopsy regime as he will be
guided to take biopsies most likely where he sees the signal or suspects tumor with conventional
illumination. To reduce this type of bias, investigators would have to predefine the biopsy site based on
preoperative imaging alone, then to approach the predefined region for determining the signal of the
optical method, finally to biopsy, irrespective of what is seen during surgery.
Tissue allocation bias type C Depending on the size of the sample, the surface of which is usually only visualized during surgery (due
to the optical character of the methods discussed and the 2D signal returned from the tissue surface) the
3D sample might harbor different types of tissue, which in turn might confound the evaluation. This
depends on how the biopsy is dissected and which fractions of the biopsy are specifically interrogated
histologically (Fig. 2). Tissue allocation bias of this type has been identified as an explanation why
OSNA (one step nuclei acid amplification) for detecting metastasis in sentinel lymph nodes in cancer
patients compared to pathological investigations were sometimes discordant, since different parts of the
same lymph nodes were tested by OSNA than by pathology (e.g., Kumagai et al. 2014).
This bias can be minimized by taking small samples or volumetrically interrogating larger samples.
Bias from biopsy frequency In many studies in the brain the number of typically collected tissue samples is rather low and the number
per patient differ. These samples are then pooled for the final analysis of measures of diagnostic
accuracy. These, however, depend on the number of samples taken in a certain brain region an entered
into the calculation. Table 2 gives an example how differences in the numbers of samples in different
regions in a single patient will directly influence measures of diagnostic accuracy.
This bias can be minimized by using statistical methods such as generalized linear mixed models or by
keeping the number of samples for patients the same.
Pooling samples from different patients If a method fails to show a signal in one patient, there will be little sampling in the tumor core. In patients
in whom the method works well, it is likely that more samples will be taken. Pooling these samples will
skew the results and overestimate the diagnostic accuracy for single patients. Pooling biopsies from
different patients without taken the dependencies of biopsies within a patient into account will, in
consequence, lead to an underestimation of the variability and of the confidence limits. Also,
calculating diagnostic measures per patient and then averaging over all patients will lead to biased
results (Table 3). Such uncritical pooling also ignores the interdependence of multiple samples in
single patients if not statistically accounted for. Effects of such clustering should be made transparent
by exactly describing the numbers of samples per patient and region. Multivariable statistical methods
accounting for clustered data and potential confounders should be applied and supported by presen-
tation of an additional patient-based analysis.
Threshold bias in methods with significant
signal-to-noise ratios
For optical methods which do not provide binary or dichotomous information (i.e., signal vs. no signal)
but rather provide optical information with a wide range of values (i.e., continuous), including low
level signals from normal tissue, that is, a background signal resulting in noise, the apparent
discrimination between diseased tissue and normal tissue will depend on the threshold which is
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overall survival, would be invariably diluted and difficult to
detect. The numbers needed to achieve statistical power for
adequately detecting improvements of survival would there-
fore be very high.
Table 4 (continued)
Bias type Explanation
selected. A high threshold will decrease the likelihood of false positive samples and thus will increase
PPV and specificity. A low threshold will reduce the likelihood of false negatives and will therefore
increase NPVand sensitivity. For instance, spectrograpical methods will return data on a continuous
scale and will be subject to this relationship, as demonstrated for 5-ALA derived porphyrin fluores-
cence (Valdes et al. 2011, Stummer et al. 2014). Fluorochromes, such as fluorescein sodium, which are
injected i.v. and present in the plasma, will lead to a background level within normal and peritumoral
tissues (Fig. 3) in a manner non-specific for tumor.
Such thresholds need to be exactly defined to minimize bias and ensure reproducibility. ROC analyses
should be considered with methods that return data on a continuous scale, evaluating various
thresholds.
Timing bias Many intraoperative imagingmethods, which rely on dyes, reveal time-dependent staining of tumor tissue
and also surrounding signal with a varying signal-to-noise ratio over time (e.g., ALA, Stummer et al.
1998,,Neira et al. 2016, Schwake et al. 2014) (Fig. 3).
Thus, results of testing for diagnostic accuracy will vary over time after administration and need to be
recorded.
Bias from methods for histological
assessment
Histological assessments are clearly an important standard of truth (reference standard) for intraoperative
optical testing. However, it is difficult even for the experienced neuropathologist to identify individual
tumor cells based on conventional stains (e.g., H&E) only. Immunohistochemical approaches might
serve to increase the likelihood of detecting tumor cells in samples, e.g., Ki67 staining, p53 or IDH1
staining, Results regarding sensitivity and specificity will vary depending on the sensitivity of
neuropathological assessments and the detection of tumor cells in the peritumoral region.
Thus, the histological methods need to be reported in detail.
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The need for a guideline for intraoperative tissue diagnosis
Intraoperative tissue diagnosis is an expanding field.
Reviews are being compiled, many of which are citing
and pooling accuracy data from various publications, the
accuracy data being based on classical definitions of
diagnostic accuracy (e.g., sensitivity and specificity)
and sometimes outcome (extent of resection and overall
survival) without further consideration on how these da-
ta were determined in the original studies. Closer scru-
tiny reveals that rarely are possible confounders and
biases accounted for or the methodology transparent
enough in the original papers to allow generalization
or comparison, i.e., ensuring internal and external
validity.
For further elucidation, we reviewed all papers evaluating
the use of fluorescence in brain tumor surgery, to determine
how possible biases, as summarized in Table 4, were
accounted for, abiding to the Preferred Reporting Item for
Systematic Reviews and Meta-Analysis (PRISMA) statement
[58]. MEDLINE/PubMed and Embrace data bases were inter-
rogated for articles in English published before October 2018
with the following syntax for title and abstracts using EndNote
X7 software (Thompson Reuters, Carlsbad, CA, USA): “gli-
oma” or “gliomas” AND “fluorescence”, “fluorescence-guid-
ance”, “fluorescence guided”, “fluorescence-guided”,
“fluorophore”, “fluorochrome”, “ALA”, “5-ALA”, “5-
Fig. 5 Hypothetical examples of validation algorithms of a new
microscope for visualizing fluorescence in a diffusely infiltrating tumor
compared to an established method. The question to be answered are:
does the new method have a similar or better diagnostic accuracy, does
the new method detect the same low or lower density of infiltrating cells
(biological assessment, left part of the diagram), does the new method
disclose the same visual margins of fluorescence (visual assessment,
right). IHC immunhistochemistry, EvG Elastica van Gieson, IDH
isocitrate dehydrogenase, GFAP glial fibrillary acidic protein, MGMT
O6-methylguanine DNA methyltransferase
Table 5 Frequency of patients and biopsies in studies summarized in
Table 2 (for studies with biopsies
N n n/N
Mean 25.3 103 5.20
Standard deviation 21.0 85.8 4.29
Minimum 3 4 0.83
Median 21 88 4
Maximum 99 354 22
N number of patients in study, n number of biopsies per study, n/N num-
ber of biopsies per patient per study
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Table 6 STARD-CNS
1. Introduction
As with the STARD initiative [11], it is the aim of this guideline to help investigators improve the design and the reporting quality of diagnostic
accuracy studies. STARD-CNS expands the original STARD guidelines [11] to encompass the area of intraoperative optical diagnostics with
special reference to the brain and gives advice for the design of respective studies, which considers the plethora of pitfalls and biases involved
in such studies. The authors feel that adherence to these recommendations will reduce the potential for inadvertent bias and to promote
comparability, reproducibility and generalizability of results obtained for various intraoperative methods of optical imaging.
These recommendations do not only pertain to fluorescence methods but to any methods that relate tissues identified intraoperatively to imaging
and/or histology, e.g., other forms of non-optical tumor identification such as navigation per se, intraoperative MRI, ultrasound, but also to
targeted fluorochromes or narrow field methods such as OCT, RAMAN, confocal imaging and others. Also, these suggestions may not only be
pertinent for gliomas but might be extended to other tumor entities in the brain as well (e.g., metastasis, meningiomas, adenomas) for which
intraoperative detection methods are being developed or employed. Furthermore, methods of intraoperative tissue detection are also being
explored for the surgery of tumors outside the CNS, where similar considerations regarding the evaluation of such methods are justified, e.g.,
for mapping of sentinel lymphatic node or identification of solid tumors by near infrared fluorescence (as reviewed in Schaafsma et al. [76]).
2. Recommendations pertaining to the design of a study
• Consider a protocol with intraoperative neuronavigation and postoperative imaging for assessing the extent of the detection signal and how
this relates to MRI morphology.
• Consider addressing a particular tissue area first based on navigation, which relates this area to imaging data, then assessing the detection
signal and finally collecting a biopsy.
• In protocols containing neuronavigation for correlating tissue signal to imaging, methods should be described that compensate for the
influence of brain shift
• Consider histological assessment of the complete biopsy (the smallest unit of resection) and not only of a part of the biopsy
• Consider expanding simple H&E histology by immunohistochemistry for better detection of infiltrating tumor cells
• Consider focusing on the PPV in conjunction with the NPV (giving an exact description of where samples were taken in relationship to
neuronavigation MR imaging). PPV is the only accuracy measurement, which does not require sampling from “normal” brain.
• Consider using objective methods (e.g., spectrography) to validate subjective optical impressions.
• Consider additional reference standards, i.e., extent of resection and outcome (safety, survival), apart from biopsies.
• Define statistical methods for confirmatory endpoints ex ante. Involve a statistician in the planning stage
(see Electronic Supplementary Material for recommendations pertaining to statistical analysis and handling of dependent and clustered samples).
• If an equivalent and sufficient number of biopsies per patient cannot be collected, consider appropriate statistical methods to adjust for varying
numbers of biopsies (see below).
• Consider randomization to analyze the usefulness of the method for improving resection rates on MRI and outcome to achieve independence
from non-therapeutic factors, such as resectability, age etc.
• In studies using a method with algorithms for identifying tumor based on a specific tissue characteristic, such as with optical properties
(reflection, fluorescence) with processing of multiple inputs to give a final algorithm for tissue identification, a validation cohort is required
to rule out algorithms only to be valid for the particular data set used for generating the algorithm (e.g., Butte et al. [15]).
_______________________________________________________________________________________________________________________
3. Checklist for reporting, expanding the STARD Checklist [11]:
Bias reduction:
• What methods were used to reduce rater bias, e.g., blinded assessments by pathologists or radiologists?
• Were optical signals validated by objective detection technology, i.e., spectrography?
• Did multiple raters address the optical signal independently?
Tissue sampling algorithms:
• Describe exactly where tissue samples are taken and give methods for documenting the location of biopsies (e.g., neuronavigation), including
the size of biopsies
• Were the location and the number of biopsies taken per patient documented?
• With time sensitive methods of detection (e.g., fluorochromes injected i.v.): Are the time points at which biopsies were taken described?
• It is recommended that the same number of samples be taken from similarly defined locations in individual patients. How was this handled?
Signal detection:
• If the methodology employs thresholding, were the thresholds and the rationale for the thresholds exactly described? How was the background
signal handled? Was ROC analysis employed for continuous data? Where values transformed?
• If the methodology requires image processing, the exact procedure and settings need to be described in a reproducible way.
• How was the technical equipment tested and maintained?
• What factors confound signal detection and how are these handled?
• Was intraobserver variability accounted for?
• If algorithms for tissue detection are constructed using multiple inputs, was an independent cohort for cross-validation included?
Reference standard
• Describe which types of histological assessment are implemented, e.g., was immunohistochemistry used for identifying tumor cells in low
density that infiltrate the brain? Which markers were assessed, e.g., Ki-67/MIB-1 staining, EGFR, GFAP, IDH1, p53, others?
• If other reference standards are used (post-OP imaging, outcome, other optical imaging methods), are these exactly described?
• What methods are used to ensure transparency in non-histological reference standards to allow comparability?
Statistical considerations:
• Was a statistician involved in the planning stage? Was a sample size calculation performed? What are the planned settings
(type I error, power, assumed effects)?
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Aminolevulinic acid”, “PPIX”, “fluorescein”, “ICG”,
“indocyanin green”, “image-guided”, or “image-guidance”.
The initial search delivered 2425 articles. After removing du-
plicates (n = 1221) and non-English articles (n = 63), all avail-
able abstracts were screened for relevance. Only articles de-
scribing clinical of fluorescence for fluorescence-guided re-
sections of brain tumors were selected and reviewed. A
cross-reference check of citations of each relevant literature
review included was performed to ensure that no relevant
studies were missed by the computed database search. A total
of 62 studies were marked as relevant for this evaluation [1, 3,
4, 7, 8, 10, 12, 16–18, 20–22, 26–28, 32–34, 36, 38–44, 49,
50, 52, 53, 56, 59–63, 66–68, 70, 72–74, 77, 80, 85, 88–90,
92, 93, 95–98, 100, 102, 103, 105, 106] (PRISMA flow dia-
gram: see Fig. 4).
Data extraction Two authors (ESM and WS) independently
extracted the following characteristics from the included stud-
ies: detection method used, study type (retro-, prospective,
randomized), tumor types evaluated, outcome measures (mea-
sures of diagnostic accuracy, qualitative or quantitative out-
come measures), numbers of patients, numbers of biopsies,
prespecified biopsy algorithm, and whether the following
sources of bias were accounted for tissue allocation biases
A, B, or C, pooling of dependent and independent samples,
timing, threshold (signal-to-noise ratios), types of stains used
(Table 4).
Results of literature review
Regarding the various confounders and biases, we were able
to determine the following:
& Tissue allocation bias type A: Only 9 of 31 studies inves-
tigating diagnostic accuracy [27, 61, 65, 74, 77, 90, 100,
101] describe biopsy locations based on the intraoperative
signal margins in a reproducible way.
& Tissue allocation bias type B: Only 10 of 31 studies [7, 26,
32, 62, 66, 72, 74, 77, 100, 101] correlate biopsy location
with tissue regions on preoperative imaging using
neuronavigation.
& Tissue allocation bias type C: No study accounts for or
gives biopsy size
& Only two studies accommodate multiple samples per pa-
tient by using mixed models with random effects for the
individual patient [74, 96] and only one study offers a
patient-based and biopsy-based analysis, taking care to
collect the same number of biopsies in a sufficient number
per patient [87].
& Only four studies have predefined statistical analysis and
sample size calculation plans [3, 85, 87, 88].
& All studies have “blinded” pathology, but only 10 go be-
yond simple H&E staining for determining the presence of
tumor cells in infiltrating tumor [1, 3, 7, 27, 38, 42, 43, 66,
77, 88], if any information is available at all.
& Only four studies use objectivemethods, such as spectrog-
raphy, for validating the visual (subjective) optical signal
[62, 90, 97] (Valdés et al. 2011: spectography; Stummer
et al. 2014, spectography; Neira et al. 2016: video pixel
intensities) in studies with visible fluorophores.
& Predefined sample collection algorithms are described
in several studies [90] (e.g., Stummer et al. 2014); how-
ever, these can mostly not be considered as being repro-
ducible if independent investigators would repeat the
study.
& The numbers of biopsies per patient are surprisingly small
in studies featuring correlations between biopsies and sig-
nal, which confounds the meaningful calculation of sensi-
tivity or specificity of a diagnostic test (Table 5). Mean
values range from 0.83 to 22 (median 4) biopsies per
patient.
& Two studies do not use reproducible reference standards
[36, 78]. The comparator is given as “helpful” or “not
helpful.”
& Although administered fluorophores will have a strong
time-dependent signal, only one study relates the time
point of biopsy collection to the time point of fluorophore
administration [62].
Table 6 (continued)
• What are the primary endpoints and statistical hypotheses?
• What is the statistical design?
• Were multiple testing procedures used for type I error control?
• Were different diagnostic tools compared? Which statistical method was used?
• Describe exactly how dependent data (biopsy within patient) and independent data (per patient) were handled.
• Are statistical methods applied to account for the clustered data structure and differences in the number of biopsies per patient
(e.g., generalized linear mixed models)?
• Describe the applied statistical methods exactly and reproducibly.
• Describe how missing data were handled.
• Report estimates of diagnostic accuracy and measures of statistical uncertainty (e.g., sensitivity, specificity, PPV, NPV, and
corresponding 95% confidence intervals). Are CI adjusted for clustered data structure?
• If possible, use dichotomous outcomes for pathology and dichotomous or continuous measures for the diagnostic tool.
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& Only one randomized study compares conventional sur-
gery to surgery with the diagnostic method [85].
Together, most of these studies provide only minimal in-
formation necessary for reproducing results and enabling
comparability or generalizability. For further illustration, we
constructed a flow chart demonstrating the design of a proto-
col that addresses many of the biases and confounders in-
volved in intraoperative assessments (Fig. 5).
Due to similar concerns regarding studies on the accuracy
of classical tests and their “mediocre” quality [11, 71], the
STARD (Standards for Reporting of Diagnostic Accuracy)
initiative was born in September 2000. Reporting guidelines
based on this initiative were consecutively published in sev-
eral journals as open access (e.g., Bossuyt et al. [11]). It was
felt that past publications with evaluations for diagnostic ac-
curacy studies often lacked information on important aspects
of design, conduct, and analysis of such studies. It was
(understandably) argued that “flaws in study design can lead
to biased results” [55], citing a report [55] that found diagnos-
tic studies with specific design features to be associated with
biased, optimistic estimates of diagnostic accuracy compared
to studies without such deficiencies. The aim of the STARD
initiative was to “to improve the quality of reporting of studies
of diagnostic accuracy” with complete and accurate reporting,
allowing “the reader to detect the potential for bias in the study
(internal validity) and to assess the generalizability and appli-
cability of the results (external validity)” [11].
The guidance summarized in the STARD guidelines
(Electronic Supplementary Material Part 2) is pertinent and
should be observed when reporting the evaluation of intraop-
erative diagnostic tests. However, the STARD guidelines do
not address the specific requirements of intraoperative diag-
nostic imaging in the brain or in other organs, as they were
designed for diagnostic tests where one subject gives one test
value which is compared to a reference standard, in order to
detect a condition of interest in that subject.
More recently the TRIPOD (Transparent Reporting of a
multivariable prediction model for Individual Prognosis Or
Diagnosis) guidelines were devised [19] with a similar in-
tention of improving reporting of diagnostic models (but
also of prognostic models). The TRIPOD guidelines could
be pertinent in the present context, e.g., if multivariable
modeling of, e.g., PPV and NPV were performed, paying
attention to variables influencing these measures, such as
tumor size, or location of biopsies. However, due to its
more general nature, this guideline is not entirely sufficient
in providing guidance for the detailed context of intraop-
erative imaging in neurosurgery.
Thus, for the novel and expanding field of intraoperative
optical diagnosis, there is an evident need for a guideline for
designing and reporting diagnostic accuracy studies.
For this purpose, we suggest expansions of the original
STARD guidelines (which may be downloaded under
https://www.elsevier.com/__data/promis_misc/ISSM_
STARD_Checklist.pdf), as summarized in Table 6, as well as
several considerations and recommendations regarding
statistics, which are added in Electronic Supplementary
Material 2.
Conclusion
In conclusion, the biases and confounders involved in reliable
and reproducible testing of diagnostic accuracy in methods of
intraoperative imaging diagnoses are many. In this rapidly
expanding field, a consensus on reporting standard is becom-
ing necessary. If investigators do not adhere to such or similar
standards, different methods or different studies using the
same visualization method simply cannot be compared.
The authors propose a guideline to this end, as suggested
and elucidated in Table 6 (references cited in Electronic
Supplementary Material [30, 46, 54, 69, 83, 104, 107]).
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